Compare CREG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CREG | NEUP |
|---|---|---|
| Founded | N/A | 1996 |
| Country | China | United States |
| Employees | N/A | 8 |
| Industry | Power Generation | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 23.0M |
| IPO Year | 2019 | N/A |
| Metric | CREG | NEUP |
|---|---|---|
| Price | $0.34 | $4.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 4.7M | 55.0K |
| Earning Date | 03-27-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $867,431.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12953.89 | N/A |
| 52 Week Low | $0.20 | $3.65 |
| 52 Week High | $2.66 | $21.31 |
| Indicator | CREG | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 17.24 | 51.05 |
| Support Level | $0.20 | $3.92 |
| Resistance Level | $1.47 | $4.56 |
| Average True Range (ATR) | 0.26 | 0.25 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 5.21 | 38.03 |
Smart Powerr Corp is a pioneer in waste energy recycling and a developer of energy efficiency solutions for various energy-intensive industries in China. It uses the Build-Operate-Transfer (BOT) model to provide energy-saving and recovery facilities for multiple energy-intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. The company offers waste energy recycling systems to companies for use in nonferrous metal plants. It constructs its projects at its customer's facility and the electricity produced is used on-site by the customer.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.